Literature DB >> 9220372

Autoradiographic localization of 5-HT1E and 5-HT1F binding sites in rat brain: effect of serotonergic lesioning.

A Fugelli1, C Moret, G Fillion.   

Abstract

5-carboxamidotryptamine (5-CT)-insensitive binding sites labelled by [3H]5-hydroxytryptamine (5-HT) in the presence of 100 nM 5-CT and 100 nM mesulergine, were examined by semi-quantitative autoradiography in rat brain. Under these conditions most of the labelled sites correspond to 5-HT1E and 5-HT1F sites. The 5-CT-insensitive binding is located mainly in cortical layer V, caudate-putamen, interpeduncular nucleus and claustrum. In cortex and caudate-putamen, a large proportion of 5-CT-insensitive sites is displaced by 250 nM sumatriptan and can be attributed to the presence of 5-HT1F receptors. A low, but significant, level of displacement by sumatriptan was observed in the choroid plexus. Lesions of serotonergic neurones by intracerebroventricular 5,7-dihydroxytryptamine injection does not significantly modify the densities of 5-HT1E or 5-HT1F binding sites. Our findings suggest that the 5-HT1F receptor has a limited distribution in rat brain, mainly located on non-serotonergic neurones.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9220372     DOI: 10.3109/10799899709039154

Source DB:  PubMed          Journal:  J Recept Signal Transduct Res        ISSN: 1079-9893            Impact factor:   2.092


  6 in total

1.  [3H]LY334370, a novel radioligand for the 5-HT1F receptor. II. Autoradiographic localization in rat, guinea pig, monkey and human brain.

Authors:  Virginia L Lucaites; Joseph H Krushinski; John M Schaus; James E Audia; David L Nelson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-04-27       Impact factor: 3.000

2.  Distribution of 5-ht(1E) receptors in the mammalian brain and cerebral vasculature: an immunohistochemical and pharmacological study.

Authors:  M T Klein; M Teitler
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

3.  Guinea pig hippocampal 5-HT(1E) receptors: a tool for selective drug development.

Authors:  Michael T Klein; Milt Teitler
Journal:  J Neurochem       Date:  2009-02-05       Impact factor: 5.372

4.  5-HT1F receptor-mediated mitochondrial biogenesis for the treatment of Parkinson's disease.

Authors:  Natalie E Scholpa; Mary K Lynn; Daniel Corum; Heather A Boger; Rick G Schnellmann
Journal:  Br J Pharmacol       Date:  2017-12-22       Impact factor: 8.739

Review 5.  Post-triptan era for the treatment of acute migraine.

Authors:  Peter J Goadsby
Journal:  Curr Pain Headache Rep       Date:  2004-10

Review 6.  Targeted 5-HT1F Therapies for Migraine.

Authors:  Marta Vila-Pueyo
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.